Previous Article | Next Article ![]()
Infection and Immunity, June 2001, p. 3728-3736, Vol. 69, No. 6
Laboratorio di Batteriologia e Micologia
Medica, Istituto Superiore di Sanità, Rome, Italy
Received 22 November 2000/Returned for modification 10 January
2001/Accepted 23 February 2001
T-cell-mediated immunity is known to play a central role in the
host response to Candida albicans. T-cell clones are
useful tools for the exact identification of fungal T-cell epitopes and the processing requirements of C. albicans antigens. We
isolated human T-cell clones from an HLA-DRB1*1101 healthy donor by
using an antigenic extract (MP-F2) of the fungus. Specific clones were T-cell receptor Fungal opportunistic
infections, in particular, those caused by Candida species,
have gained considerable significance as a cause of morbidity and
mortality. Mucosal candidiasis is frequent in immunocompromised
patients, especially those infected by the human immunodeficiency virus
or those affected by idiopathic CD4+ T
lymphocytopenia (6, 15, 34, 44), while deep-seated candidiasis is highly prevalent in neutropenic, bone marrow transplant patients (28, 30, 53). Finally, a large incidence of
vaginal infection by Candida is recorded in otherwise
healthy women of premenopausal age (24).
Although some controversy exists about the final effector mechanisms of
anti-Candida protection (9, 45, 46), cellular immune responses, in particular, those relying on or regulated by T
lymphocytes, are generally considered of utmost importance for the
induction of a protective state. In particular, this notion has been
well established with experimental models of infection with
Candida albicans, the most pathogenic species of the genus. This fungus is an ordinary human commensal, capable in this state of
inducing persistent humoral and cellular responses in healthy subjects,
as witnessed by the presence of antibodies against various cell surface
constituents, intense proliferative responses of peripheral blood
mononuclear cells (PBMC), and delayed-type hypersensitivity following
stimulation with Candida antigens (24). All
these responses are representative of an active immunization
state. Thus, oral candidiasis in human immunodeficiency
virus-infected subjects is believed to be caused by the acquired
T-lymphocyte deficiency, and the onset of mucosal candidiasis in these
patients is closely related to both numerical and functional decreases in CD4+ T lymphocytes (6, 15, 31, 37, 44,
51).
Human T-cell lines and T-cell clones (TCC) specific for C. albicans have rarely been generated and described in the
literature (29, 33), although they could be useful tools
in the study of immune responses to Candida. TCC could
provide direct clues about the nature and requirements for antigen
processing of complex natural glycoconjugates, such as the
mannoproteins, which are major T-cell antigens of this fungus
(10, 12, 27, 52). They could also provide direct evidence
of immunodominant epitopes of the pathogen and might be useful for
immunoreconstitution therapy of some forms of candidiasis (33,
51). However, we are unaware of any approach specifically
devoted to understanding immune responses in candidiasis by the use of
Candida-specific human TCC.
The 65-kDa mannoprotein (MP65) has long been demonstrated to be a major
target of T-cell responses in humans (3, 4, 7, 10, 26,
52). Some properties of this major Candida antigen
with regard to potential immunoprophylactic or immunotherapeutic activity, or even for use as an immunodiagnostic reagent, have been
disclosed. However, the importance of MP65 relative to that of other
C. albicans antigens in inducing a T-cell response could be
derived only from a comparison with other products. In addition, little
information on the antigenic availability of MP65 and its processing
requirements could be obtained by use of PBMC for measurement of
the response to the antigen. Some putative epitopes could be identified
by studying the proliferative response of PBMC to MP65 peptides derived
from tryptic digestion (26), but a full definition of the
antigenic properties and epitopes of MP65 could not be established by
use of the polyclonal T-cell populations represented by PBMC.
The aims of this work were to establish C. albicans
antigen-specific human TCC and to examine the extent to which they
recognize MP65 as a major antigen among soluble fungal products.
Efforts were also made to further characterize T-cell epitopes among
the most immunogenic peptides of MP65 in an attempt to define HLA restriction. Finally, we compared some processing features of natural
(glycosylated) and recombinant (nonglycosylated) MP65 (32)
with the aim of discovering a possible role of polysaccharides in the
processing requirements and T-cell recognition of this major antigen of
C. albicans.
C. albicans antigens and MP65 synthetic
peptides.
The C. albicans mannoprotein-rich fraction
MP-F2 was prepared as described elsewhere (11). Briefly,
MP-F2 was separated by ion-exchange chromatography with DEAE-Sephadex
A-50 from a crude mannoprotein extract of C. albicans yeast
cells. MP-F2 was composed of >90% mannan and 8% protein. Biochemical
and immunological characterization of this antigen has been reported
elsewhere (52).
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3728-3736.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Antigenic Properties and Processing Requirements of 65-Kilodalton
Mannoprotein, a Major Antigen Target of Anti-Candida
Human T-Cell Response, as Disclosed by Specific Human T-Cell
Clones
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
and CD4+/CD8
and showed a T-helper type 1 cytokine profile (production of gamma interferon and not interleukin-4). The large majority of these
clones recognized both the natural (highly glycosylated) and the
recombinant (nonglycosylated) 65-kDa mannoprotein (MP65), an MP-F2
minor constituent that was confirmed to be an immunodominant antigen of
the human T-cell response. Surprisingly, most of the clones recognized
two synthetic peptides of different MP65 regions. However, the peptides
shared the amino acid motif IXSXIXXL, which may be envisaged as
a motif sequence representing the minimal epitope recognized by these
clones. Three clones recognized natural and pronase-treated MP65 but
did not detect nonglycosylated, recombinant MP65 or the peptides,
suggesting a possible role for polysaccharides in T-cell recognition of
C. albicans. Finally, lymphoblastoid B-cell lines were
efficient antigen-presenting cells (APC) for recombinant MP65 and
peptides but failed to present natural, glycosylated antigens,
suggesting that nonprofessional APC might be defective in processing
highly glycosylated yeast proteins. In conclusion, this study provides
the first characterization of C. albicans-specific human
T-cell clones and provides new clues for the definition of the cellular
immune response against C. albicans.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Reagents. Phytohemagglutinin (PHA) was obtained from Murex (Dartford, United Kingdom). Recombinant interleukin-2 (IL-2) was a kind gift from EuroCetus (Milan, Italy), and tetanus toxoid (TT) was obtained from Chiron (Siena, Italy). Tritiated thymidine was purchased from Amersham (Little Chalfont, United Kingdom). Fluorescein isothiocyanate (FITC)-labeled anti-CD4 and anti-CD8 were purchased from Becton Dickinson (Mountain View, Calif.), and anti-major histocompatibility complex (anti-MHC) class II MAb L243 was obtained from the American Type Culture Collection, Rockville, Md. An FITC-conjugated mouse immunoglobulin G (IgG) control (Becton Dickinson) served for background determination.
Media. RPMI 1640 medium was supplemented with 100 U of kanamycin/ml, 1 mM L-glutamine, 1 mM sodium pyruvate, and 1% nonessential amino acids (complete medium). When needed, 10% fetal calf serum (FCS; Gibco Laboratories, Grand Island, N.Y.) or 5% human serum (Sigma) was added. IL-2 was used at 10 to 100 U/ml.
MP-F2-specific TCC. MP-F2-specific TCC were derived from PBMC of a DRB1*1101 (DR5) normal donor as previously described (40, 41). Briefly, PBMC were purified from heparinized blood on a density gradient (Lymphoprep; Nycomed Pharma AS, Oslo, Norway) and resuspended in complete medium supplemented with 5% autologous serum in the presence or absence of 5 µg of MP-F2/ml. After 5 and 10 days, 10 and 100 U of IL-2/ml, respectively, were added to the cultures. After 5 additional days, cultures showing significant cell growth were considered positive. Cells were counted and cloned by limiting dilution in the presence of 5 × 105 irradiated PBMC, 1 µg of PHA/ml, and 100 U of IL-2/ml. After 10 to 15 days, growing cultures were expanded in medium containing 100 U of IL-2/ml and finally tested for MP-F2 specificity by a proliferation assay using irradiated autologous PBMC prepulsed or not prepulsed with MP-F2 at 5 µg/ml. MP-F2-specific clones were maintained and expanded in cultures with 25- to 35-day cycles of restimulation with PHA and irradiated PBMC.
Epstein-Barr virus-transformed LCL and DC. Lymphoblastoid B-cell lines (LCL) were established from the same donor by infecting 106 PBMC in an overnight incubation with Epstein-Barr virus-containing supernatant from the B.869 cell line and then were cultured in complete medium supplemented with 10% FCS and 0.5 µg of cyclosporine/ml. Dendritic cells (DC) were prepared by isolation on Percoll gradients of monocytes from PBMC as described previously (47). After 5 days of culturing in the presence of granulocyte-macrophage colony-stimulating factor and IL-4, cells were treated with antigen or apoptotic cells overnight (1, 2) and then were treated with lipopolysaccharide (Sigma) for 6 h to induce final differentiation. After extensive washings, cells were used as antigen-presenting cells (APC) for MP-F2-specific TCC in proliferation experiments.
Proliferation assay. Proliferative responses were measured with triplicate cultures (220 µl) in 96-well flat-bottom plates that routinely contained 3 × 104 to 5 × 104 responder TCC and either 105 irradiated PBMC or 3 × 104 to 5 × 104 LCL as APC in 10% FCS-containing complete medium. C. albicans and S. cerevisiae antigens were used at a final concentration of 5 µg (polysaccharide for MP-F2 and M-sMP and protein for purified molecules) per milliliter. Synthetic peptides were used at 10 µg/ml. In dose-response tests, twofold dilutions from 5 to 1.25 µg/ml (mannoproteins and proteins) or from 10 to 0.312 µg/ml (peptides) were used.
In inhibition experiments, autologous LCL were incubated with peptides at 2 µg/ml for 2 h at 4°C. LCL were then washed and incubated for 1 h with decreasing concentrations of anti-HLA-DR (from 1:4 to 1:64 twofold dilutions of L243 cell culture supernatant) before TCC were added for the proliferation assay. In all proliferation assays, tritiated thymidine was added at 5 µCi/well after 48 h of culturing, and cells were harvested 18 h later. Results were expressed as mean counts per minute in triplicate wells.Cytokine determinations.
The production of cytokines by
selected MP-F2-specific TCC, chosen from among those showing different
reactivities, was measured with pooled supernatants from 0.2-ml
cultures containing 5 × 105 irradiated
autologous PBMC/ml and 5 × 105 TCC/ml, with
or without MP-F2 at 10 µg/ml. Culture supernatants were collected
after 48 h of culturing. Gamma interferon (IFN-
) and IL-4 were
measured using a commercial enzyme-linked immunosorbent assay according
to manufacturer instructions (Quantikine; R&D Systems, Inc.,
Minneapolis, Minn.).
Phenotypic analysis. Aliquots of 2 × 105 TCC were harvested from macrocultures, washed twice with cold 0.1% bovine serum albumin-phosphate-buffered saline, and stained with FITC-conjugated anti-CD4 or anti-CD8 MAb. An FITC-conjugated mouse IgG control (Becton Dickinson) served for background determination. After washings, cells were resuspended in medium suitable for FACScan (Becton Dickinson) analysis.
Fluorescence intensity was evaluated by computerized analysis of histograms generated from at least 5,000 viable cells (5).| |
RESULTS |
|---|
|
|
|---|
Generation of MP-F2-specific TCC.
To generate specific human
TCC, we used the highly immunogenic mannoprotein-rich fraction of
C. albicans, MP-F2 (52), and PBMC from an
HLA-DRB1*1101 (DR5) high-responder donor, as in previous experiments
(32). Fifty-five clones from among 300 screened were
selected for a specific proliferative response to MP-F2. All of the
specific clones were tested for immunophenotyping by flow cytometry and
were found to be alpha or beta T-cell receptor (TCR-
/
)
CD4+/CD8
cells. The
specificity of TCC for MP-F2 was verified by use of three proliferation
assays with irradiated autologous PBMC prepulsed or not prepulsed with
MP-F2. In addition, none of the clones tested proliferated in the
presence of Sc-rMP65 or TT (Table 1).
Furthermore, clonality was assessed via a subcloning test, which showed
100% MP-F2 specificity of growing subcloned cells. Interestingly, all TCC proliferated with MP-F2 in the presence of autologous PBMC as APC
(Fig. 1A) but not with autologous LCL
(Fig. 1B). Since T-cell-secreted cytokines are critical regulatory
components of immunological responses, we also measured the production
of IFN-
and IL-4 in supernatants of MP-F2-stimulated TCC cultures
with autologous PBMC as APC. All TCC tested secreted IFN-
but not IL-4, suggesting that MP-F2 prevalently induces a typical T-helper type
1 (Th1) immune response and substantially confirming previous results from experimental animal models and PBMC proliferation assays (4, 38).
|
|
Identification of MP65 as an immunodominant antigen in MP-F2.
MP-F2 is a fraction from a crude mannoprotein extract of yeast cells of
C. albicans separated from a whole cellular extract of the
fungus by ion-exchange chromatography (52). MP65 is
quantitatively a minor molecular constituent of MP-F2 and of other
C. albicans fractions, such as the secretory hyphal
constituent M-sMP, but is recognized as a main target of the human
T-cell response against C. albicans (26). We
therefore evaluated which fraction of MP-F2-specific clones recognized
MP65 so as to have a direct measure of the relative immunodominance of
this latter mannoprotein in the anti-C. albicans cellular
response. As shown in Fig. 2, the
majority of the MP-F2-specific TCC proliferated when tested with
MP65-pulsed APC, suggesting that, although a minor molecular component
of the preparation, MP65 represents its major antigen recognized by T
cells.
|
|
A motif sequence for MP65 peptide recognition by T cells.
A
previous study with MP65-stimulated PBMC identified two internal
peptides as antigenic determinants of the molecule (26). Thus, in the attempt to identify major epitopes of MP65 in
HLA-DRB1*1101 (DR5) subjects, we first investigated the TCC responses
toward these two putative T-cell epitopes. Two pairs of peptides
(T1a-T1b and T2a-T2b) were synthesized to reproduce the sequences of
two previously described (26) tryptic peptides of MP65,
derived from amino acids 142 to 164 (peptide T2) and 182 to 204 (peptide T1) of MP65 (32). Figure
4A shows two representative TCC with different reactivities toward natural MP65, Ca-rMP65, and synthetic peptides T1a, T1b, T2a, and T2b. Clone 0.3/26 reacted with both natural MP65 and recombinant MP65 as well as with peptides T1b, T2b,
and T2a. The same results were obtained with the majority of the TCC
tested, although different clones showed differences in the peptide
resulting in the highest proliferation. Clone 0.3/18, on the other
hand, showed a proliferative response when tested with natural MP65 but
not with Ca-rMP65 or with the peptides used. Interestingly, this latter
clone is one of the few which also proliferated in the presence of
pronase-treated antigens (Fig. 3). The inability of this clone to
respond to peptides or to Ca-rMP65 (which is nonglycosylated) and its
ability to respond to protein-digested preparations suggest that the
polysaccharide moiety of the molecule could be involved, at least in
part, in the T-cell recognition of this C. albicans antigen.
|
|
|
Processing requirement of MP65.
In screening our clones, we
noted that autologous LCL were unable to act as MP-F2 APC; in fact,
none of the clones was induced to proliferate with natural MP65-pulsed
LCL (Fig. 1B). The same results were obtained when LCL from an
HLA class II-compatible healthy subject were used (data not
shown). We next assayed the capacity of autologous LCL to act as APC
using different preparations of MP65, such as Ca-rMP65, MP-F2, and
synthetic peptides, as sources of MP65 epitopes. As shown in Fig.
6, only Ca-rMP65 and peptides were
efficiently presented by LCL to MP-F2-specific TCC. The failure of LCL to present natural MP65 might be related to the polysaccharide moiety of the glycoprotein, which could impair the uptake and/or the
processing of natural MP65 in B cells. The possible lack of processing
machinery to digest mannoproteins in B cells was investigated in
cross-presentation experiments. LCL pulsed with or without MP-F2 were
irradiated to induce apoptosis and then incubated with autologous DC.
After incubation with apoptotic LCL, DC were induced to maturation with
lipopolysaccharide and then used as APC for MP65-specific clones.
Figure 6 shows that DC previously exposed to apoptotic LCL
pulsed with MP-F2 were able to present MP65 epitopes to TCC.
|
| |
DISCUSSION |
|---|
|
|
|---|
TCC are useful tools in the dissection of immune responses to self and non-self antigens. The isolation of antigen-specific TCC is crucial when the exact definition of antigenic specificity, as well as epitope dominance and functional assets of individual T-cell responses, is needed (14, 43, 54). Mucosal candidiasis relies upon some local or systemic deficiency in T-cell responses (6, 9, 10, 12, 18, 24, 37). Therefore, the analysis of these responses would greatly benefit from careful assessment of fine antigen recognition, phenotype, and function of TCC. Such an analysis would also provide potentially therapeutic tools for an attempt to reconstitute a protective response by administration of TCC which were deleted or altered in their specificity or function as a result of the immune deficiency.
Despite these promising perspectives, Candida-specific TCC have only sporadically been investigated (29). For instance, Sieck et al. showed that Candida-specific T-cell lines (antigen not specified) allowed fungus elimination from infected mice (50). More recently, Manca et al. demonstrated the preserved antigen specificity of Candida-reactive T-cell lines in AIDS subjects, despite the well-known numerical loss of specific clones (33). Overall, we are unaware of any published report specifically devoted to an understanding of defined antigen specificity in candidiasis through the use of human TCC.
One of the reasons for the paucity of TCC generation and usage in research on anticandidal immunity is the relatively low-grade definition of Candida antigens involved in the stimulation of T-cell responses and recognized as dominant T-cell epitopes. We have long been studying a 65-kDa mannoprotein of C. albicans, MP65, a structural and secretory component of the fungus that is particularly abundant in extracellular fractions of hyphal cells (4, 7, 26, 27). The reasons for focusing on this constituent were twofold. First, it is the main glycosylated member of a mannoprotein-rich fraction, MP-F2, capable of inducing an appreciable level of protection against murine candidiasis (10). Second, it was recognized as the main stimulating Candida antigen by peripheral blood lymphocytes from almost all healthy subjects tested (28, 32). Moreover, in animals immunized with MP-F2, the MP65 constituent was the principal one recognized by the animal splenocytes and was a strong stimulator of a delayed-type hypersensitivity reaction in vivo. More recently, the gene encoding the protein component of MP65 was cloned, and a recombinant product that was also strongly antigenic in human PBMC cultures was generated (32).
In order to understand more thoroughly the antigenic properties of MP65, we have generated human TCC using MP-F2 to stimulate PBMC from a healthy donor. It is generally believed that, when an antigen is added to PBMC in vitro, memory-experienced cells represent the population of CD4+ T cells that specifically proliferate. These cells originate from in vivo-primed lymphocytes upon presentation by professional APC of peptides with a high level of binding to MHC class II molecules, selected by enzymatic digestion of the antigen. The large majority of MP-F2-reactive clones generated were indeed reactive with MP65, a minor component of the MP-F2 mixture, indicating that in vivo MP65 is an immunodominant antigen that, more than others, is able to expand the specific T-lymphocyte population.
All of the clones tested were CD4+ and secreted
IFN-
but not IL-4 upon specific antigenic challenge, indicating a
clear Th1 phenotype (4). It has been suggested that a Th1
response is an essential constituent of anti-Candida
protection, although Th1 and Th2 responses may vary in different body
sites (16, 22). A close cooperation between innate and
adaptive responses appears to be required for anti-Candida
protection, as also evidenced by the various strategies of
immunoevasion adopted by the fungus (21). In this context,
the clear definition of MP65-specific TCC as Th1 lymphocytes would
indicate a potential role of these cells in the recognition of and
possibly the defense against Candida invasion in humans.
Experiments are in progress to assess the capacity of this constituent
to induce protection in various experimental models of candidiasis.
We also wanted to investigate which epitopes were recognized by our MP65-specific TCC. TCC were isolated from an HLA-DRB1*1101 (DR5) donor whose PBMC responded to MP-F2 and MP65 peptides, T1 and T2, which have been previously shown to be inducers of human PBMC proliferation in several subjects tested (26). Peptides T1 and T2 were synthesized as two overlapping pairs (T1a-T1b and T2a-T2b) to reproduce the sequences of tryptic peptides of MP65 (Table 2). We noted that each clone recognizing the homologous pair T2a-T2b also recognized T1b. This result was rather surprising given that all lymphocytes of a TCC share the same TCR, thus virtually recognizing a single MHC-peptide complex. The possibility that every TCC was not a clone but was a mixture of two clones, one recognizing T1a or T1b and the other recognizing T2a or T2b peptides, exists in theory but is highly improbable. In fact, this reactivity was observed in all the Ca-rMP65-recognizing TCC, which have been isolated from different cultures grown after limiting dilution at 0.3 to 1 cell/well. The double reactivity with peptides T1a or T1b and T2a or T2b was confirmed by using subclones of three different primary TCC. A close insight into the peptide sequences suggested that T2a, T2b, and T1b have some residues (I, S, I, and L) at fixed positions in their sequences, flanked by other amino acids nonrelevant for peptide recognition. In the peptide sequence of a T-cell epitope, at least two amino acids are required to bind the MHC class II groove and two are required to engage the TCR of a specific T lymphocyte (36, 55). In this regard, it is of interest to note that peptide T1a has IXSXI but lacks the terminal lysine of the hypothesized motif, and it is not recognized by the majority of TCC which recognize the other three peptides. In addition, only a minority of other TCC recognize peptide T1a. The motif sequence is not present in any region of S. cerevisiae MP65, which is not recognized at all by our MP65-specific clones.
The availability of distinct MP65-specific TCC and both the natural (glycosylated) protein and the recombinant (nonglycosylated) protein allowed the analysis of the relevance of glycosylation in the specific recognition of this antigen by human T lymphocytes. First, we observed that three of our TCC were reactive with MP-F2, natural MP65, and M-sMP-P but not with recombinant MP65 or the synthetic peptides T1a, T1b, T2a, and T2b. These observations, although inconclusive, suggest possible T-cell recognition of the polysaccharide moiety, which accounts for about one-third of the whole molecule and is apparently composed of O-linked mannosyl residues only, given the absence in the molecule of a putative N-glycosidic site (17, 25, 32). Glycopeptides (25) and glycolipids (39, 49) have in fact been identified as defined T-cell epitopes presented in the context of classical MHC molecules and CD1 molecules, respectively. In addition, T-cell recognition of a glycosidic moiety has been suggested in the definition of epitopes in human allergens (20, 48). Thus, the possibility exists that complex polysaccharides linked to C. albicans proteins are involved in T-cell recognition of this pathogen. Given that most surface antigens of the fungus are indeed polysaccharidic in nature, studies aimed at a better definition of possible T-cell recognition of polysaccharides are currently in progress.
Second, we observed that LCL were unable to present natural MP65 but retained the ability to present Ca-rMP65 and peptides. However, DC were able to stimulate MP65-specific TCC after phagocytosis of natural MP65-pulsed apoptotic LCL (1, 2, 56). These data suggest that LCL can concentrate but not digest natural MP65. LCL have been previously described to have limitations in processing ability (35). These limitations have been ascribed to restriction or diversity in other APC in the proteolytic machinery used to cleave proteins into MHC class II binding peptides (13, 19). For MP65, however, LCL were able to digest the recombinant protein, revealing the efficiency of the protein-digesting machinery. Thus, it can be hypothesized that the enzymatic digestion of antigen in nonprofessional APC, such as LCL, is highly affected by the presence of O-linked mannoside chains that could hinder the cleavage of certain protein substrates. Interestingly, natural MP65 was demonstrated to be totally resistant to any protease (trypsin, chymotrypsin, or endoproteinase Asp-N) treatment used to partially or completely digest the molecule, unless it was previously denatured by heat (100°C) or sodium dodecyl sulfate (26).
The inability of nonprofessional APC to process natural MP65 could have functional consequences in AIDS patients, who have a high predisposition to mucosal candidiasis (6, 15). Because the availability of functional professional APC in lymph nodes decreases with the progression of the disease (23, 42), it can be hypothesized that the relative importance in activating T lymphocytes of nonprofessional APC, such as B lymphocytes, progressively increases. Thus, the inability of B cells to present a major antigen of C. albicans may contribute, together with the decrease in the level of specific CD4+ T cells, to the onset of disease.
In conclusion, in this paper we report the first characterization of C. albicans-specific human TCC and demonstrate the immunodominance of MP65 among C. albicans soluble products. We also provide evidence on the relevance of polysaccharides in the processing and T-cell recognition of MP65. Finally, we propose a motif sequence that, in HLA-DRB1*1101 (DR5) subjects, may represent the characterizing epitope of MP65 useful for possible immune intervention. Further studies using donors with other HLA class II haplotypes are required to extend the epitope mapping of MP65.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported in part by Istituto Superiore di Sanità, Programma Nazionale AIDS, grants 50C/D and 50C/B.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratorio di Batteriologia e Micologia Medica, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. Phone: 39 06 4990 2659. Fax: 39 06 4938 7112. E-mail: r.nisini{at}iss.it.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Albert, L. M.,
S. F. Pearce,
L. M. Francisco,
B. Sauter,
P. Roy,
R. L. Silverstein, and N. Bhardwaj.
1998.
Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes.
J. Exp. Med.
188:1359-1368 |
| 2. | Albert, L. M., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89[CrossRef][Medline]. |
| 3. |
Ausiello, C. M.,
G. C. Spagnoli,
M. Boccanera,
I. Casalinuovo,
F. Malavasi,
C. U. Casciani, and A. Cassone.
1986.
Proliferation of human peripheral blood mononuclear cells induced by Candida albicans and its cell wall fractions.
J. Med. Microbiol.
22:195-202 |
| 4. |
Ausiello, C. M.,
F. Urbani,
S. Gessani,
G. C. Spagnoli,
M. J. Gomez, and A. Cassone.
1993.
Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans.
Infect. Immun.
61:4105-4111 |
| 5. | Bartoleschi, C., R. Nisini, R. Biselli, A. Casciaro, and A. Fattorossi. 1994. Flow cytometric analysis of cell function: cytosolic Ca++ modulation in human polymorphonuclear leukocytes and T lymphocytes. Eur. J. Histochem. 38:47-52. |
| 6. | Brawner, D. L., and A. J. Hovan. 1995. Oral candidiasis in HIV-infected patients. Curr. Top. Med. Mycol. 6:113-125[Medline]. |
| 7. | Bromuro, C., A. Torosantucci, M. J. Gomez, F. Urbani, and A. Cassone. 1994. Differential release of an immunodominant 65 kDa mannoprotein antigen from yeast and mycelial forms of Candida albicans. J. Med. Vet. Mycol. 32:447-459[Medline]. |
| 8. |
Cappellaro, C.,
V. Mrsa, and W. Tanner.
1998.
New potential cell wall glucanases of Saccharomyces cerevisiae and their involvement in mating.
J. Bacteriol.
180:5030-5037 |
| 9. | Casadevall, A., A. Cassone, F. Bistoni, J. E. Cutler, W. Magliani, J. W. Murphy, L. Polonelli, and L. Romani. 1998. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med. Mycol. 36:95-105. |
| 10. | Cassone, A., F. De Bernardis, C. M. Ausiello, M. J. Gomez, M. Boccanera, R. La Valle, and A. Torosantucci. 1998. Immunogenic and protective Candida albicans constituents. Res. Immunol. 149:289-299[CrossRef][Medline]. |
| 11. | Cassone, A., and A. Torosantucci. 1991. Immunological moieties of the cell wall, p. 89-107. In R. Prasad (ed.), Candida albicans. Springer-Verlag, Berlin, Germany. |
| 12. |
Chaffin, W. L.,
J. L. Lopez-Ribot,
M. Casanova,
D. Gozalbo, and J. P. Martinez.
1998.
Cell wall and secreted proteins of Candida albicans: identification, function, and expression.
Microbiol. Mol. Biol. Rev.
62:130-180 |
| 13. | Chen, B. P., R. DeMars, and P. M. Sondel. 1987. Presentation of soluble antigen to human T cells by products of multiple HLA-linked loci: analysis of antigen presentation by a panel of cloned, autologous, HLA-mutant Epstein-Barr virus-transformed lymphoblastoid cell lines. Hum. Immunol. 18:75-91[CrossRef][Medline]. |
| 14. |
Chiari, R.,
G. Hames,
V. Stroobant,
C. Texier,
B. Maillere,
T. Boon, and P. G. Coulie.
2000.
Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules.
Cancer Res.
60:4855-4863 |
| 15. | Coleman, D. C., D. E. Bennett, D. J. Sullivan, P. J. Gallagher, M. C. Henman, D. B. Shanley, and R. J. Russell. 1993. Oral Candida in HIV infection and AIDS: new perspectives/new approaches. Crit. Rev. Microbiol. 19:61-82[Medline]. |
| 16. |
De Bernardis, F.,
G. Santoni,
M. Boccanera,
E. Spreghini,
D. Adriani,
L. Morelli, and A. Cassone.
2000.
Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans.
Infect. Immun.
68:3297-3304 |
| 17. |
Deck, B. M.,
P. Sjolin,
E. R. Unanue, and J. Kihlberg.
1999.
MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues.
J. Immunol.
162:4740-4744 |
| 18. | Deepe, G. S., Jr. 1997. Prospects for the development of fungal vaccines. Clin. Microbiol. Rev. 10:585-596[Abstract]. |
| 19. | Demotz, S., P. M. Matricardi, C. Irle, P. Panina, A. Lanzavecchia, and G. Corradin. 1989. Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways. J. Immunol. 143:3881-3886[Abstract]. |
| 20. |
De Palma, R.,
S. Wu,
F. Sallusto,
G. Di Felice,
P. Martucci,
D. Geraci,
P. Colombo,
C. Troise,
G. Sacerdoti,
A. Nocera, and J. Gorski.
1999.
Use of antagonist peptides to inhibit in vitro T cell responses to Par j1, the major allergen of Parietaria judaica pollen.
J. Immunol.
162:1982-1987 |
| 21. |
d'Ostiani, C. F.,
G. Del Sero,
A. Bacci,
C. Montagnoli,
A. Spreca,
A. Mencacci,
P. Ricciardi-Castagnoli, and L. Romani.
2000.
Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo.
J. Exp. Med.
191:1661-1674 |
| 22. |
Elahi, S.,
G. Pang,
R. Clancy, and R. B. Ashman.
2000.
Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis.
Infect. Immun.
68:5771-5777 |
| 23. |
Fauci, A. S.,
G. Pantaleo,
S. Stanley, and D. Weissman.
1996.
Immunopathogenic mechanisms of HIV infection.
Ann. Intern. Med.
124:654-663 |
| 24. | Fidel, P. L., Jr., and J. D. Sobel. 1994. The role of cell-mediated immunity in candidiasis. Trends Microbiol. 2:202-206[CrossRef][Medline]. |
| 25. |
Franco, A.,
T. Yokoyama,
D. Huynh,
C. Thomson,
S. G. Nathenson, and H. M. Grey.
1999.
Fine specificity and MHC restriction of trinitrophenyl-specific CTL.
J. Immunol.
162:3388-3394 |
| 26. |
Gomez, J. M.,
B. Maras,
A. Barca,
R. La Valle,
D. Barra, and A. Cassone.
2000.
Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen Candida albicans.
Infect. Immun.
68:694-701 |
| 27. | Gomez, J. M., A. Torosantucci, S. Arancia, B. Maras, L. Parisi, and A. Cassone. 1996. Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Infect. Immun. 64:2577-2584[Abstract]. |
| 28. | Grossi, P., C. Farina, R. Fiocchi, and D. Dalla Gasperina. 2000. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 70:112-116[CrossRef][Medline]. |
| 29. |
Hermann, E.,
W. J. Mayet,
O. Klein,
A. W. Lohse,
C. Trautwein,
I. Michiels,
T. Poralla, and K. H. Meyer zum Buschenfelde.
1991.
Candida arthritis: cellular immune responses of synovial fluid and peripheral blood lymphocytes to Candida albicans.
Ann. Rheum. Dis.
50:697-701 |
| 30. | Hoppe, J. E., M. Klausner, T. Klingebiel, and D. Niethammer. 1997. Retrospective analysis of yeast colonization and infections in paediatric bone marrow transplant recipients. Mycoses 40:47-54[Medline]. |
| 31. | Kaplan, J. E., D. Hanson, M. S. Dworkin, T. Frederick, J. Bertolli, M. L. Lindegren, S. Holmberg, and J. L. Jones. 2000. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30:S5-S14. |
| 32. |
La Valle, R.,
S. Sandini,
M. J. Gomez,
F. Mondello,
G. Romagnoli,
R. Nisini, and A. Cassone.
2000.
Generation of a recombinant 65-kilodalton mannoprotein (MP65), a major antigen target of cell-mediated immune response to Candida albicans.
Infect. Immun.
68:6777-6784 |
| 33. | Manca, F., D. Fenoglio, E. Franchin, D. Saverino, G. Li Pira, F. Buffa, D. Bignardi, L. Del Pup, and G. Palu. 1997. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS. Gene Ther. 4:1216-1224[CrossRef][Medline]. |
| 34. | Manchado Lopez, P., J. M. Ruiz de Morales, I. Ruiz Gonzalez, and M. A. Rodriguez Prieto. 1999. Cutaneous infections by papillomavirus, herpes zoster and Candida albicans as the only manifestation of idiopathic CD4+ T lymphocytopenia. Int. J. Dermatol. 38:119-121[CrossRef][Medline]. |
| 35. | Mandell, R. B., J. A. Hank, B. P. Chen, H. I. Robins, and P. M. Sondel. 1987. Differential antigen presentation by heat-treated peripheral blood mononuclear cells and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL): heated EBV-LCL present alloantigen and soluble antigen but are deficient in the stimulation of autologous EBV-LCL primed T cells. Hum. Immunol. 19:163-177[CrossRef][Medline]. |
| 36. | Mazza, G., D. Housset, C. Piras, C. Gregoire, S. Y. Lin, J. C. Fontecilla-Camps, and B. Malissen. 1998. Glimpses at the recognition of peptide/MHC complexes by T-cell antigen receptors. Immunol. Rev. 163:187-196[CrossRef][Medline]. |
| 37. | McCarthy, G. M. 1992. Host factors associated with HIV-related oral candidiasis. A review. Oral Surg. Oral Med. Oral Pathol. 73:181-186[CrossRef][Medline]. |
| 38. |
Mencacci, A.,
A. Torosantucci,
R. Spaccapelo,
L. Romani,
F. Bistoni, and A. Cassone.
1994.
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.
Infect. Immun.
62:5353-5360 |
| 39. |
Moody, D. B.,
M. R. Guy,
E. Grant,
T. Y. Cheng,
M. B. Brenner,
G. S. Besra, and S. A. Porcelli.
2000.
CD1b-mediated T cell recognition of a glycolipid antigen generated from mycobacterial lipid and host carbohydrate during infection.
J. Exp. Med.
192:965-976 |
| 40. | Nisini, R., P. M. Matricardi, A. Fattorossi, R. Biselli, and R. D'Amelio. 1992. Presentation of superantigen by human T cell clones: a model of T-T cell interaction. Eur. J. Immunol. 22:2033-2039[Medline]. |
| 41. | Nisini, R., M. Paroli, D. Accapezzato, F. Bonino, F. Rosina, T. Santantonio, F. Sallusto, A. Amoroso, M. Houghton, and V. Barnaba. 1997. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J. Virol. 71:2241-2251[Abstract]. |
| 42. | Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358[CrossRef][Medline]. |
| 43. | Pathan, A. A., K. A. Wilkinson, R. J. Wilkinson, M. Latif, H. McShane, G. Pasvol, A. V. Hill, and A. Lalvani. 2000. High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. Eur. J. Immunol. 30:2713-2721[CrossRef][Medline]. |
| 44. | Powderly, W. G., K. H. Mayer, and J. R. Perfect. 1999. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res. Hum. Retrovir. 15:1405-1412[CrossRef][Medline]. |
| 45. |
Romani, L.
2000.
Innate and adaptive immunity in Candida albicans infections and saprophytism.
J. Leukoc. Biol.
68:175-179 |
| 46. | Romani, L., F. Bistoni, and P. Puccetti. 1997. Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. Chem. Immunol. 68:110-135[Medline]. |
| 47. |
Sallusto, F., and A. Lanzavecchia.
1994.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
J. Exp. Med.
179:1109-1118 |
| 48. | Sallusto, F., R. Poupot, M. Clergue, R. DePalma, and J. J. Fournie. 2000. A flavonoid sulfate antigen activates human alphabeta CD8+ Th2 lymphocytes in pollen allergy. Eur. J. Immunol. 30:964-968[CrossRef][Medline]. |
| 49. | Shamshiev, A., A. Donda, T. I. Prigozy, L. Mori, V. Chigorno, C. A. Benedict, L. Kappos, S. Sonnino, M. Kronenberg, and G. De Libero. 2000. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity 13:255-264[CrossRef][Medline]. |
| 50. |
Sieck, T. G.,
M. A. Moors,
H. R. Buckley, and K. J. Blank.
1993.
Protection against murine disseminated candidiasis mediated by a Candida albicans-specific T-cell line.
Infect. Immun.
61:3540-3543 |
| 51. | Stearn, B. F., and M. A. Polis. 1994. Prophylaxis of opportunistic infections in persons with HIV infection. Clevel. Clin. J. Med. 61:187-194[Medline]. |
| 52. | Torosantucci, A., C. Bromuro, M. J. Gomez, C. M. Ausiello, F. Urbani, and A. Cassone. 1993. Identification of a 65-kDa mannoprotein as a main target of human cell-mediated immune response to Candida albicans. J. Infect. Dis. 168:427-435[Medline]. |
| 53. | Viviani, A. M., A. M. Tortorano, C. Malaspina, M. Colledan, G. Paone, G. Rossi, G. Bordone, and A. Pagano. 1992. Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. Eur. J. Epidemiol. 8:433-436[CrossRef][Medline]. |
| 54. |
Vogt, H. M.,
E. Goulmy,
F. M. Kloosterboer,
E. Blokland,
R. A. de Paus,
R. Willemze, and J. H. Falkenburg.
2000.
UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition.
Blood
96:3126-3132 |
| 55. | Young, A. C., S. G. Nathenson, and J. C. Sacchettini. 1995. Structural studies of class I major histocompatibility complex proteins: insights into antigen presentation. FASEB J. 9:26-36[Abstract]. |
| 56. |
Yrlid, U., and M. J. Wick.
2000.
Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells.
J. Exp. Med.
191:613-624 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»